DLGAP5 protects glioblastoma cells against DNA damage through E2F1-transcripted RAD51AP1

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis and high resistance to therapy.
• DNA damage repair is a critical factor in GBM progression and therapeutic resistance.
• The role of discs large homolog associated protein 5 (DLGAP5) in GBM is not well understood.

Purpose of the Study:

• To investigate the role of DLGAP5 in glioblastoma multiforme.
• To elucidate the molecular mechanisms by which DLGAP5 influences DNA damage repair in GBM.
• To assess the therapeutic potential of targeting DLGAP5 in GBM.

Main Methods:

• Analysis of DLGAP5 expression in GBM patient data.
• In vitro studies involving DLGAP5 knockdown in GBM cells.
• Investigation of the E2F1/RAD51AP1 signaling pathway.
• Xenograft models of GBM tumors.

Main Results:

• DLGAP5 is upregulated in GBM and associated with poor patient prognosis.
• DLGAP5 knockdown inhibits GBM cell proliferation, induces apoptosis, and causes DNA damage.
• DLGAP5 regulates E2F1-mediated transcription of RAD51AP1, a key DNA repair protein.
• DLGAP5 knockdown suppresses tumor growth in vivo.

Conclusions:

• DLGAP5 promotes GBM cell survival by protecting against DNA damage through the E2F1/RAD51AP1 pathway.
• DLGAP5 represents a potential therapeutic target for novel anti-GBM strategies.
• Targeting DLGAP5 may enhance the efficacy of DNA damage-inducing therapies for GBM.